Many Investors Still Treating Gilead: 4 Launches This Year Could Prove Them Wrong
Gilead sits at a crossroads: the HIV backbone remains strong, but a quartet of new launches could reshape the company...
Review critical factors to watch before investing in Dividend Aristocrats Etf, such as dividend stability, sector concentration, and expense ratios.
25,039 articlesGilead sits at a crossroads: the HIV backbone remains strong, but a quartet of new launches could reshape the company...
A regulatory shift hit the live entertainment market, and StubHub stock plummeted this week. This deep dive explains ...
Berkshire Hathaway slashed its Amazon holding by 77% in the fourth quarter, leaving a lean position and sparking rene...
Investors looking at cannabis real estate need to understand how Innovative Industrial Properties reports earnings. T...
Kaspi.kz faces a pivotal year as it expands its super app, grows its loan book, and navigates regional headwinds. Thi...
A top hedge fund stepping up its Duolingo stake highlights conviction in the language-learning platform. This article...
The Ethereum Foundation has quietly moved 5,000 ETH to BitMine in a $10 million over-the-counter trade, marking its s...
Bluesky is carving a new path in social media by using an open, federated protocol. This article explains what Bluesk...
Investors are watching Crinetics' Q1 2026 results for clues on milestones, cash runway, and partnerships. This guide ...
Live events are back, but investors want proof StubHub can grow profits. This guide breaks down the stubhub (stub) 20...
A growing chorus of advisers argues that stop letting money checking idle is costly. A Roth IRA can offer tax-free re...
Intel stock has surged on AI optimism and cost discipline. This article explains the drivers behind the rally, the ri...